News & Events

July 10, 2018

VIDAC PHARMA ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early…
June 20, 2018

VIDAC PHARMA TO PRESENT A POSTER AT THE EACR25 2018 MEETING

Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the…
April 04, 2018

VIDAC PHARMA TO PRESENT AN IMMUNO-METABOLISM POSTER AT THE 2018 AACR ANNUAL MEETING 2018

Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present an immono-metabolism poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The poster…
January 23, 2018

VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE

Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and dermatology-focused biopharmaceutical company, today announced that Oren M. Becker, PhD, President and Chief Executive Officer, will present at the 2018 BIO CEO & Investor…
Dec 06, 2017

VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM

Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and…
Oct 12, 2017

VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS

Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102…
Jan 01, 2017

VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS

Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused…
Dec 12, 2016

VIDAC PHARMA PHASE 2A STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION

Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused…
Jul 29, 2016

VIDAC PHARMA ANNOUNCES THE INNITIATION OF A PHASE 2A STUDY OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 30, 2016

VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT

Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 29, 2016

Vidac Pharma Completes $9 Million Series A Financing I Advances Phase 2 Studies with VDA-1102 In Actinic Keratosis

Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage…
Feb 25, 2016

Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development…
Dec 30, 2015

Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis

Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development…
Oct 15, 2014

Vidac Pharma Appoints Dr. Chaim Brickman as Vice President of Clinical Affairs

Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development…
Aug 19, 2014

Vidac Pharma Appoints Dr. Paul Salama as Vice President of Chemistry, Manufacturing, and Control

Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development…

 

back Factsheet